{
  "abstract": "Objectives Oesophageal adenocarcinoma (OAC) has a poor prognosis as patients typically present with late-stage disease. Gastro-oesophageal reflux disease (GORD) can lead to Barrett’s oesophagus (BO), the only known precursor to OAC. Detecting patients with BO allows interventions to prevent development of late-stage OAC and improve survival. Non-endoscopic devices, such as EndoSign, coupled with biomarkers trefoil factor 3, atypia and p53 have demonstrated performance for diagnosis of BO. The CYTOPRIME 2 Study was designed to assess the feasibility of implementing this test in a real-world community care setting.Methods Patients with chronic GORD identified from general practitioner electronic records were invited to have a capsule sponge test (ie, EndoSign) in the community, of which 1815 completed the test.Results 266 (14.7%) had a subsequent endoscopy based on a positive test. 97 patients (5.3%) of the total group, or 36% of those endoscoped, had BO confirmed at endoscopy of whom 90 (93%) had intestinal metaplasia on histology and 3 had low-grade dysplasia (3%). In addition, 6 patients (0.3%), or 2.2% of those endoscoped, had cancer—4 with OAC, 1 squamous cell oesophageal tumour and 1 early stage gastric cancer. Patients’ and clinicians’ acceptability of the test was high.Conclusions Non-endoscopic capsule sponge testing can be used successfully in community settings to diagnose BO and minimally symptomatic oesophagogastric cancer in a target population of patients with GORD. Patients diagnosed with BO can be offered prospective surveillance to detect precancerous changes and allow endoscopic therapies to prevent late-stage oesophageal cancer.",
  "authors": [
    {
      "affiliations": [
        "Cyted Ltd, Cambridge, UK"
      ],
      "name": "Monica Della Rosa"
    },
    {
      "affiliations": [
        "Cyted Ltd, Cambridge, UK"
      ],
      "name": "Ruchika Kulkarni"
    },
    {
      "affiliations": [
        "Cyted Ltd, Cambridge, UK"
      ],
      "name": "Richard Henry Hardwick"
    },
    {
      "affiliations": [
        "Cyted Ltd, Cambridge, UK"
      ],
      "name": "Basirat Afinowi"
    },
    {
      "affiliations": [
        "Early Cancer Institute, University of Cambridge, Cambridge, UK",
        "Early Detection Programme, CRUK Cambridge Centre, Cambridge, UK"
      ],
      "name": "Rebecca C Fitzgerald"
    },
    {
      "affiliations": [
        "Cyted Ltd, Cambridge, UK"
      ],
      "name": "Sarah Killcoyne"
    },
    {
      "affiliations": [
        "Cyted Ltd, Cambridge, UK"
      ],
      "name": "Marcel Gehrung"
    },
    {
      "affiliations": [
        "Department of Gastroenterology, East and North Hertfordshire NHS Trust, Stevenage, UK",
        "School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK"
      ],
      "name": "Danielle L Morris"
    },
    {
      "affiliations": [
        "Cyted Ltd, Cambridge, UK",
        "Early Cancer Institute, University of Cambridge, Cambridge, UK",
        "Early Detection Programme, CRUK Cambridge Centre, Cambridge, UK",
        "Department of Gastroenterology, East and North Hertfordshire NHS Trust, Stevenage, UK",
        "School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK",
        "General Practice, NHS Suffolk and North East Essex Integrated Care Board West Suffolk Office, Bury Saint Edmunds, UK"
      ],
      "name": "CYTOPRIME2 Care Teams"
    },
    {
      "affiliations": [
        "General Practice, NHS Suffolk and North East Essex Integrated Care Board West Suffolk Office, Bury Saint Edmunds, UK"
      ],
      "name": "Peter Holloway"
    }
  ],
  "title": "Feasibility of primary care-based early detection of Barrett’s oesophagus and oesophageal adenocarcinoma in patients with reflux using capsule sponge testing: real-world insights from the CYTOPRIME 2 Study",
  "uid": "19180b50-ca6b-53a8-92d4-69883b1ca033"
}